# China NMPA Drug Inspection - Qingsong Traditional Chinese Medicine Pieces Co., Ltd., Pingliang City, Gansu Province - leech

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/qingsong-traditional-chinese-medicine-pieces-co-ltd-pingliang-city-gansu-province/63b073dc-250e-4bc9-9b87-5e8d7aadc1ae/
Source feed: China

> China NMPA drug inspection for Qingsong Traditional Chinese Medicine Pieces Co., Ltd., Pingliang City, Gansu Province published December 30, 2019. Drug: leech. The Gansu Provincial Drug Administration issued a Drug Quality Announcement on December 30, 2019, identifying significan

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Drug Quality Announcement from Gansu Provincial Drug Administration
- Company Name: Qingsong Traditional Chinese Medicine Pieces Co., Ltd., Pingliang City, Gansu Province
- Publication Date: 2019-12-30
- Drug Name: leech
- Inspection Finding: Total ash content and pH level did not meet the requirements.
- Action Taken: The relevant market supervision and management departments have taken necessary control measures such as sealing and seizing, and have filed or are in the process of filing cases against the units involved in the products in accordance with relevant laws and regulations. The results of the handling will be made public within three months.
- Summary: The Gansu Provincial Drug Administration issued a Drug Quality Announcement on December 30, 2019, identifying significant quality deficiencies across 15 batches of drugs from 14 manufacturers. Led by Gansu Yalan Pharmaceutical Co., Ltd., the implicated companies failed to meet standards outlined in the Chinese Pharmacopoeia 2015 Edition, Part I. Key violations included deficiencies in quality control parameters such as elevated total aerobic bacteria count, issues with physical properties like appearance and pH, and purity concerns related to total ash, acid-insoluble ash, loss on ignition, and extractives. Some products also demonstrated non-compliance in content determination, and the presence of heavy metals and harmful elements. In response, regulatory authorities have implemented immediate control measures, including sealing and seizing the non-compliant products. Investigations into the responsible units have been initiated or are underway, with findings slated for public release within three months. Furthermore, municipal and prefectural market supervision bureaus are tasked with enhanced oversight, compelling the involved companies to thoroughly investigate the root causes, develop and execute rectification plans, and effectively mitigate future risks to ensure public safety and product integrity.

Company: https://www.globalkeysolutions.net/companies/qingsong-traditional-chinese-medicine-pieces-co-ltd-pingliang-city-gansu-province/46fe8dd3-f5cc-44ad-9668-5bdf9ff5ac53/